CMOPF Stock Chart & Stats
$126.00
--
Market closed
$126.00
--
Day’s Range― - ―
52-Week Range$64.95 - $169.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.08K
Market Cap
$1.32B
Enterprise Value$963.95
Total Cash (Recent Filing)$195.28M
Total Debt (Recent Filing)$4.33M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.95%
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume3,235
30 Day Avg. Volume1,078
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$159.20Price Target Upside26.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)$130.37M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and substantial equity provide durable financial optionality: cushions operating volatility, funds near-term R&D or regulatory activities, and lowers refinancing risk. This balance-sheet strength supports execution and partnership flexibility over the next 2–6 months.
Ability To Generate High Margins In Strong YearsThe company has demonstrated it can scale revenue with very high net margins when demand aligns, indicating product-market fit and operational leverage. That structural profitability potential supports longer-term value capture if revenue stability returns.
Partnering/licensing And Supply Revenue ModelA business model combining internal sales with licensing, milestone and royalty streams reduces commercialization cost and shares development risk. That diversified revenue architecture provides recurring and non-linear upside and enhances capital efficiency over time.
Bears Say
Sharp Revenue Decline And Margin SwingA large drop in sales and a rapid margin deterioration indicate reliance on a narrow set of drivers or episodic revenue events. Such structural revenue sensitivity reduces earnings visibility and makes medium-term planning, investment and partner commitments more uncertain.
Negative Operating And Free Cash Flow In 2025Cash burn reverses prior self-funding capability and forces reliance on external financing or partner funding for operations and development. Weaker cash generation raises execution risk, can delay projects, and limits agility over the coming months.
Historic Earnings Volatility With Intermittent LossesRepeated swings between high profit years and loss years suggest exposure to cyclical demand, concentration risk or one-off events. Persistent earnings inconsistency undermines long-term forecasting, partner negotiating power and steady reinvestment capacity.
COSMO Pharmaceuticals N.V. News
CMOPF FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was $64.95 and its highest was $169.90 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is $1.32B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 243 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of $0 by $0.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of $2.463 which represents an annual dividend yield of 2.95%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of $0 in its last earnings report, expectations of $0. Following the earnings report the stock price went up 8.165%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CMOPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
CMOPF Stock 12 Month Forecast
Average Price Target
$159.20
▲(26.35% Upside)
Ownership Overview
―
Insiders
7.76% Mutual Funds
0.05% Other Institutional Investors
88.50% Public Companies and
Individual Investors